System and method for delivering protease inhibitors

Inactive Publication Date: 2014-08-07
BORDOLOI BIOTECH
View PDF6 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patent is about a system and method for delivering a protease inhibitor to a fibrin sealant in a way that can help prevent the degradation of the sealant in vivo. The system includes a biodegradable microsphere that encapsulates the protease inhibitor and is combined with fibrinogen and thrombin to form a mixture. This mixture is then applied to a surgical wound site with a proteolytic environment, where the inhibitor can release and help inhibit the activity of proteases. This system can provide a longer lifespan for fibrin sealant in vivo and can be used in a method for delayed fibrin-based blood clot degradation at a surgery.

Problems solved by technology

Rapid degradation of clots is not always welcome, particularly when deep wounds take longer to heal.
However, currently available treatments using Aprotinin often struggle to provide a safe and reliable therapeutic method to delay the degradation of fibrin clots, or fibrinolysis.
Thus less plasmin is available to dissolve and / or degrade fibrin-based blood clots.
As stated above, lower plasmin levels result in a longer fibrinolysis and degradation profile for a given fibrin-based blood clot.
Currently available technology may not adequately meet the challenges presented by the undesirable diffusion of a protease inhibitor, such as TA, from a sealant.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • System and method for delivering protease inhibitors
  • System and method for delivering protease inhibitors
  • System and method for delivering protease inhibitors

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0084]A preparation of TA in PLGA at 5 percent loading for sustained release was prepared having the ingredients listed in the Table 1 below:

TABLE 1(1)TA with an average particle diameter of 3.3 micron where the particlediameter does not exceed 13 micron(2)PLGA with an intrinsic viscosity of 0.44 dl / gm inhexafluoroisopropanol (hereinafter “HFIP”) at 25° C. and a glasstransition temperature of 37° C. to 44° C. as established bydifferential scanning calorimetry(3)Dichloromethane (“DCM”) where a suspension of TA in DCMmay be dried and run by thermogravimetric analysis (“TGA”) andx-ray powder diffraction (“XRPD”) to demonstrate that DCM hasnot altered the structure of TA(4)Polydimethylsiloxane (“PDMS”) with a viscosity of 350 cSt(5)Cyclomethicone, for example D-5 cyclic siloxane,decamethylcyclopentasiloxane, also known as Mirasil ® CM-5 fromBluestar Silicones

[0085]The formulation of Example 1 was prepared as follows:[0086]1. Make a 2.5 wt. percent solution of PLGA in DCM by dissolving 0...

example 2

[0094]A preparation of TA in PLGA at 30 percent loading for sustained release was prepared according to method set forth in Example 1 above with the following alterations.

[0095]The formulation of Example 2 was prepared as follows:[0096]1. Use a proportionately higher amount of TA, e.g. 0.166 g TA, to prepare a loading of 30 wt. percent TA in PLGA.[0097]2. Also, penta-cyclomethicone, the cyclic pentamer, may be replaced with a cyclic tetramer, D-4, for example from Bluestar Silicones.

example 3

[0098]The formulation of Example 2 (i.e. 30 wt. percent TA in TA / PLGA microspheres) was characterized as follows:[0099]1. Use an optical or a Scanning Electron Microscope (“SEM”) to characterize as shown in FIG. 1A or 1B. The average diameter of the TA / PLGA microsphere was observed to be approximate 40 micron.[0100]2. Use Confocal-Raman Spectroscopy to characterize the 30 wt. percent TA in TA / PLGA microspheres as shown in FIGS. 2A, 2B and 2C. As shown in FIGS. 2A, 2B and 2C, it was observed that TA was distributed towards the center of the PLGA microsphere, which was desirable for sustained release.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Water solubilityaaaaaaaaaa
Biodegradabilityaaaaaaaaaa
Swelling volumeaaaaaaaaaa
Login to View More

Abstract

The disclosed invention provides a system and method of artificially retarding fibrin-based blood clot degradation via the sustained release of a protease inhibitor, such as, for example, aprotinin or tranexamic acid (“TA”). The sustained release of the protease inhibitor is accomplished through incorporation within a biodegradable polymer microsphere to produce a protease inhibitor formulation. Next, the formulation along with fibrinogen and thrombin is applied to a wound site where an outer surface of the polymer microsphere degrades in a proteolytic environment to expose and release the incorporated protease inhibitor to the surrounding hydrogel or sealant or clot matrix at the wound site.

Description

PRIORITY[0001]This Utility Application claims the benefit of U.S. Provisional Patent Application No. 61 / 760,973, filed on Feb. 5, 2013.BACKGROUND[0002]1. Technical Field[0003]The present invention generally relates to a system and a method for delaying the dissolution of blood clots, and more particularly, the present invention provides a method and a delivery system for a material which delays the degradation of fibrin based blood clots.[0004]2. Background of the Invention[0005]Fibrin is insoluble protein produced by the body in response to bleeding, and is a major component in blood clots. Fibrin based clots form naturally during hemostasis, which is a process that stops bleeding by converting blood from a liquid to a solid. Fibrin is formed from fibrinogen, a soluble protein produced by the liver. Fibrinogen is converted at a wound site into fibrin by the action of thrombin, a clotting enzyme, in instances of tissue damage. Fibrin molecules may combine to form fibrin threads that...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/16
CPCA61K9/16A61K31/195A61K9/0053A61K9/14A61K9/1647A61K9/50A61L24/001A61L24/0015A61L24/0042A61L24/043A61L26/0052A61L26/0061A61L26/0066A61L26/009A61L31/16A61L2300/418A61L2300/434A61L2300/604A61L2300/622A61L2400/04
InventorBORDOLOI, BINOY K.SARMA, NAYAN JYOTIEISENBERG, RODNEY L.
OwnerBORDOLOI BIOTECH